Drug Type asPNA |
Synonyms- |
Target |
Action inhibitors |
Mechanism miR-21 inhibitors(microRNA 21 inhibitors), Epigenetic drug |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Triple Negative Breast Cancer | Preclinical | United States | 26 May 2023 | |
| Triple Negative Breast Cancer | Preclinical | United States | 26 May 2023 |





